Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open Label, Randomized Study to Evaluate Safety And Effectiveness Of The Tivoli® Biodegradable Polymer Rapamycin-Eluting Stent and The FIREBIRD2® Rapamycin-Eluting Coronary CoCr Stent For Treatment Coronary Revascularization

NCT01681381 is registered in ClinicalTrials.gov with Essen Technology (Beijing) Co., Ltd. as lead sponsor.

NCT NCT01681381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01681381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open Label, Randomized Study to Evaluate Safety And Effectiveness Of The Tivoli® Biodegradable Polymer Rapamycin-Eluting Stent and The FIREBIRD2® Rapamycin-Eluting Coronary CoCr Stent For Treatment Coronary Revascularization
Lead sponsor
Essen Technology (Beijing) Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
September 30, 2012
Completion date
September 30, 2018
Enrollment
2,790 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, coronary artery lesions,primary, coronary disease, furcation lesion of coronary artery, ischemic heart disease, myocardial ischemia